Verona Pharma plc (VRP.L) (VRP) News Today Add Share Share Headlines Stock Analysis All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Analysts Have Conflicting Sentiments on These Healthcare Companies: Alphatec Holdings (ATEC), Verona Pharma (VRNA) and DENTSPLY SIRONA (XRAY)February 28, 2025 | markets.businessinsider.comCanaccord raises Verona Pharma target to $72; maintains buyFebruary 13, 2025 | msn.comVerona Pharma price target raised to $72 from $44 at CanaccordFebruary 12, 2025 | markets.businessinsider.comVerona Pharma stock soars to all-time high of $62.09February 12, 2025 | msn.comVerona Pharma Keeps Hitting New HighsFebruary 4, 2025 | msn.comVerona Pharma stock soars to all-time high of $56.49January 30, 2025 | msn.comWhy Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This WeekJanuary 17, 2025 | msn.comVerona Pharma's Options Frenzy: What You Need to KnowJanuary 16, 2025 | benzinga.comWhy Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This WeekJanuary 16, 2025 | msn.comVerona Pharma stock soars to all-time high of $51.88January 16, 2025 | msn.comVerona Pharma initiated with a Buy at Roth MKMJanuary 10, 2025 | markets.businessinsider.comVerona Pharma’s Ohtuvayre: Unique COPD Solution Drives Buy Rating Amid Market Potential and Revenue GrowthJanuary 10, 2025 | markets.businessinsider.comVerona Pharma price target raised to $57 from $44 at TruistJanuary 8, 2025 | markets.businessinsider.comVerona Pharma price target raised to $74 from $64 at Wells FargoJanuary 8, 2025 | markets.businessinsider.comVerona Pharma price target raised to $42 from $36 at H.C. WainwrightNovember 6, 2024 | markets.businessinsider.comVerona Pharma Receives Buy Rating Amid Strong Financial Performance and Growth ProspectsNovember 6, 2024 | markets.businessinsider.comVerona Pharma Q3 2024 Earnings PreviewNovember 1, 2024 | msn.comVerona Pharma (NASDAQ:VRNA) Stock, Short Interest ReportOctober 11, 2024 | benzinga.comPiper Sandler Remains a Buy on Verona Pharma (VRNA)October 3, 2024 | markets.businessinsider.comBuy Rating for Verona Pharma as Ohtuvayre Shows Promise in COPD Treatment and Expansion PotentialOctober 1, 2024 | markets.businessinsider.comVerona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024September 30, 2024 | markets.businessinsider.comVerona Pharma Rings the Closing BellSeptember 18, 2024 | nasdaq.comBuy Rating Affirmed for Verona Pharma Amid Strategic Partnership and Market Potential for Novel COPD TreatmentSeptember 18, 2024 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Verona Pharma (VRNA)August 22, 2024 | markets.businessinsider.comBuy Rating Affirmed for Verona Pharma Amid Ohtuvayre Launch Success and Promising Pipeline ExpansionAugust 9, 2024 | markets.businessinsider.comOptimistic Buy Rating for Verona Pharma Amidst Strong Ohtuvayre™ Launch and Expanding Clinical TrialsAugust 9, 2024 | markets.businessinsider.comBuy Rating on Verona Pharma: Promising Launch and Strong Financials Signal Market Growth PotentialAugust 9, 2024 | markets.businessinsider.comVerona Pharma plc (VRNA) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | seekingalpha.comVRNA Stock Earnings: Verona Pharma Misses EPS for Q1 2024May 9, 2024 | msn.comVerona Pharma plc (VRNA)April 24, 2024 | finance.yahoo.comStrong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial StrategyMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed on Verona Pharma Ahead of Ensifentrine’s Expected FDA Approval and Strong Financial StandingMarch 4, 2024 | markets.businessinsider.comMichael Austwick Joins Verona Pharma as Non-Executive DirectorFebruary 1, 2024 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Verona Pharma (VRNA)January 3, 2024 | markets.businessinsider.comVerona Pharma enters upto $400M debt facilityJanuary 2, 2024 | msn.comBTIG Reaffirms Their Buy Rating on Verona Pharma (VRNA)January 1, 2024 | markets.businessinsider.comBuy Rating for Verona Pharma: Strong Potential of Ensifentrine, Attractive Entry Point and Solid FinancialsNovember 3, 2023 | markets.businessinsider.comPositive Outlook for Verona Pharma’s Stock Amid Anticipated FDA Approval and Promising Market Potential for EnsifentrineOctober 25, 2023 | markets.businessinsider.comVerona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate UpdateOctober 19, 2023 | benzinga.comVerona Pharma: De-Risked COPD Biotech Play, Approval Likely Coming SoonSeptember 5, 2023 | msn.comCanaccord Genuity Reiterates Verona Pharma Plc - ADR (VRNA) Buy RecommendationSeptember 2, 2023 | msn.comExpert Ratings for Verona PharmaSeptember 1, 2023 | benzinga.comChristina Ackermann Joins Verona Pharma as Non-Executive DirectorAugust 31, 2023 | benzinga.comH.C. Wainwright Keeps Their Buy Rating on Verona Pharma (VRNA)August 4, 2023 | markets.businessinsider.comVerona Pharma to Present at 43rd Annual Canaccord Growth ConferenceJuly 26, 2023 | benzinga.comVerona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate UpdateJuly 20, 2023 | benzinga.comTruist Securities Reiterates Verona Pharma Plc - ADR (VRNA) Buy RecommendationJune 28, 2023 | msn.comWedbush Reiterates Verona Pharma Plc - ADR (VRNA) Outperform RecommendationJune 28, 2023 | msn.comBTIG Sticks to Their Buy Rating for Verona Pharma (VRNA)June 28, 2023 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Verona Pharma (VRNA)May 25, 2023 | markets.businessinsider.com Remove Ads Get Verona Pharma plc (VRP.L) News Delivered to You Automatically Sign up to receive the latest news and ratings for VRP and its competitors with MarketBeat's FREE daily newsletter. Email Address VRP Media Mentions By Week VRP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRP News Sentiment▼-0.800.52▲Average Medical News Sentiment VRP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRP Articles This Week▼00▲VRP Articles Average Week Remove Ads Get Verona Pharma plc (VRP.L) News Delivered to You Automatically Sign up to receive the latest news and ratings for VRP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:VRP) was last updated on 3/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored[BREAKING NOW] Gold Is Literally Moving—And So Is Its PriceFor decades, I’ve accurately predicted every major gold move—because the signs were always there. Now, I’m ...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWhy 2026 will be a disaster for many AmericansWall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc (VRP.L) Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma plc (VRP.L) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
